Last reviewed · How we verify
GEMIGLIPTIN LS15-0444
Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose.
Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | GEMIGLIPTIN LS15-0444 |
|---|---|
| Also known as | Zemiglo |
| Sponsor | Sanofi |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting DPP-4, gemigliptin prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), allowing these hormones to accumulate and enhance glucose-dependent insulin secretion. This mechanism reduces blood glucose levels in patients with type 2 diabetes while minimizing hypoglycemia risk since insulin secretion is glucose-dependent.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEMIGLIPTIN LS15-0444 CI brief — competitive landscape report
- GEMIGLIPTIN LS15-0444 updates RSS · CI watch RSS
- Sanofi portfolio CI